Department of Dermatology, St. George Hospital, Sydney, NSW, Australia.
School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, Australia.
Expert Opin Pharmacother. 2024 Aug;25(12):1657-1665. doi: 10.1080/14656566.2024.2393280. Epub 2024 Sep 3.
The review article explores the evolving role of Bruton's tyrosine kinase (BTK) inhibitors in immune-mediated dermatological conditions, addressing significant gaps in current treatment approaches.
The review comprehensively discusses the mechanisms of action of BTK inhibitors, including irreversible and reversible inhibitors. Clinical applications of BTK inhibitors in dermatological diseases such as pemphigus, chronic spontaneous urticaria (CSU), hidradenitis suppurativa (HS), systemic lupus erythematosus (SLE), and atopic dermatitis are explored, highlighting recent advancements and ongoing clinical trials. Potential advantages of BTK inhibitors over existing therapies and challenges in translating preclinical findings to clinical outcomes are discussed.
EXPERT OPINION/COMMENTARY: BTK inhibitors represent a promising therapeutic avenue for immune-mediated dermatological conditions, offering oral administration, targeted pathway inhibition, and a favorable safety profile compared to biologic therapies. Ongoing research and clinical trials hold the potential to address unmet needs and reshape the therapeutic landscape in dermatology.
这篇综述文章探讨了布鲁顿酪氨酸激酶（BTK）抑制剂在免疫介导的皮肤疾病中的作用不断变化，针对当前治疗方法中的重大空白。
这篇综述全面讨论了 BTK 抑制剂的作用机制，包括不可逆和可逆抑制剂。探讨了 BTK 抑制剂在天疱疮、慢性自发性荨麻疹（CSU）、化脓性汗腺炎（HS）、系统性红斑狼疮（SLE）和特应性皮炎等皮肤病中的临床应用，强调了最近的进展和正在进行的临床试验。讨论了 BTK 抑制剂相对于现有疗法的潜在优势，以及将临床前发现转化为临床结果所面临的挑战。
专家意见/评论：BTK 抑制剂为免疫介导的皮肤疾病提供了一种有前途的治疗途径，与生物疗法相比，它具有口服给药、靶向途径抑制和良好的安全性。正在进行的研究和临床试验有可能满足未满足的需求，并重塑皮肤病学的治疗格局。
